

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: December 03, 2008 Signature: Sharon M. Sintich/48,484  
(Sharon M. Sintich)

Docket No.: 30847/2051-004  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Anna Helgadottir et al.

Application No.: 10/769,744

Confirmation No.: 6429

Filed: January 30, 2004

Art Unit: 1614

For: SUSCEPTIBILITY GENE FOR  
MYOCARDIAL INFARCTION, STROKE,  
AND PAOD; METHODS OF TREATMENT

Examiner: S.V. Gembeh

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Applicants submit herewith copies of foreign patents and non-patent literature listed in the attached form SB/08 in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an

admission that any patent, publication or other information referred to therein is “prior art” for this invention unless specifically designated as such.

This Information Disclosure Statement is filed after the mailing date of an Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)). Accordingly, the fee of \$180.00 pursuant to 37 CFR 1.17(p) will be paid by credit card herewith. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30847/2051-004.

Dated: December 03, 2008

Respectfully submitted,

By Sharon M. Sintich/48,484

Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicants